

Conference Program and Schedule

Sunday, March 21, 2010

13:00-15:00 **Educational Session 1:
Omics and Bioinformatics**
E102

Chairperson: Olli-P. Kallioniemi, Finland Institute for Molecular Medicine, Helsinki, Finland

From canceromics research to personalized cancer therapies

Olli-P. Kallioniemi, Finland Institute for Molecular Medicine, Helsinki, Finland

The role of informatics in translational research: The interplay of epidemiology, clinical studies, and discovery research*

Jacob Koehler, Eli Lilly and Company, Indianapolis, IN, USA

Title to be announced

John N. Weinstein, UT M. D. Anderson Cancer Center, Houston, TX, USA

13:00-15:00 **Educational Session 2:
Translational and Clinical
Trial Design**
Forum

Chairperson: Eric H. Rubin, Merck Research Laboratories, North Wales, PA, USA

Approaches to solving the combinations problem in oncology therapeutics

Eric H. Rubin, Merck Research Laboratories, North Wales, PA, USA

Translational genomics in clinical trials

Carlos M. Caldas, Cancer Research UK, Cambridge, United Kingdom

Title to be announced

Laura J. van't Veer, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

15:15-17:15 **Educational Session 3:
GWAS vs. Systems Biology**
Forum

Chairperson: Stephen J. Chanock, National Cancer Institute, Bethesda, MD, USA

Genome-wide association studies in cancer: Insights in cancer etiology*

Stephen J. Chanock, National Cancer Institute, Bethesda, MD, USA

Understanding melanoma using GWAS and systems biology*

Julia A. Newton Bishop, University of Leeds, Leeds, United Kingdom

Etiological clues from breast cancer GWAS*

Montserrat Garcia-Closas, NCI-DCEG, Rockville, MD, USA

15:15-17:15 **Educational Session 4:
Functional Imaging: Getting
Beyond FDG-PET**
E102

Chairperson: E. G. Elisabeth de Vries, University Center, Groningen, The Netherlands

Functional imaging: Beyond FDG*

Patricia M. Price, Christie Hospital NHS Trust, Manchester, United Kingdom

Functional imaging: Getting beyond FDG-PET*

E. G. Elisabeth de Vries, University Medical Center Groningen, Groningen, The Netherlands

PET tracer for therapy monitoring*

Hans-Jürgen Wester, Technische Universität München, Munich, Germany

17:15-18:00 **Coffee Break**
Forum Lounge

18:00-19:00 **Keynote Session**
Forum

Chairpersons: Alexander M.M. Eggermont, Erasmus Medical Center, Rotterdam, The Netherlands and **Susan E. Bates**, National Cancer Institute, Bethesda, MD, USA

Finding mechanisms and biomarkers of drug resistance in cancer*

René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands

19:00-21:00 **Opening Reception**
Ruby Lounge

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Conference Program and Schedule

Monday, March 22, 2010

08:30-10:30 **Plenary Session 1:
Translational Medicine in
Breast Cancer Research
Forum**

Chairperson: Nadia Harbeck, University of Cologne, Cologne, Germany

Targeting PI3K in breast cancer

José Baselga, Vall d'Hebron University Hospital, Barcelona, Spain

Genomic architecture characterizes tumor progression paths and fate in breast cancer patients*

Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Oslo, Norway

Amplifying the apoptotic actions of estrogen to treat metastatic breast cancer

V. Craig Jordan, Lombardi Comprehensive Cancer Center, Washington, DC, USA

10:30-11:30 **Coffee Break**
Forum Lounge

10:30-12:30 **Poster Session A**
Forum Lounge

12:30-14:00 **Lunch/Networking Break**
Ruby Lounge

14:00-16:00 **Concurrent Session 1:
Mutations in Malignancy
Forum**

Chairperson: Marco A. Pierotti, National Cancer Institute, Milan, Italy

Target mutation: The dark side of the targeted therapies*

Marco A. Pierotti, National Cancer Institute, Milan, Italy

Genetic alterations in melanoma: Implications for disease classification and therapy stratification

Boris C. Bastian, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Mutations and expression profile to guide treatment in sarcomas and GIST*

Jean-Yves Blay, INSERM U-453, Lyon, France

14:00-16:00 **Concurrent Session 2:
Immunotherapy
E102**

Chairperson: Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands

Personalized chemotherapy of cancer based on immune parameters*

Laurence Zitvogel, Institute Gustave-Roussy, Villejuif, France

Adoptive T cell transfer: Autografting cultured, specific T cells to treat cancer

James Chung-Yin Yang, National Cancer Institute, Bethesda, MD, USA

Development of therapeutic cancer vaccine and construction of clinical research network in Japan*

Yusuke Nakamura, University of Tokyo Human Genome Center, Tokyo, Japan

16:00-16:15 **Coffee Break**
Forum Lounge

16:15-18:15 **Plenary Session 2:
Translational Medicine
in Lung Cancer Research
Forum**

Chairperson: Giuseppe Giaccone, National Cancer Institute, Bethesda, MD, USA

The impact of genomic changes on the treatment of lung cancer*

Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA, USA

The genomic landscape in lung cancer*

Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias I Pujol, Badalona, Spain

Small cell lung cancer: A forgotten disease?

Giuseppe Giaccone, National Cancer Institute, Bethesda, MD, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Conference Program and Schedule

Tuesday, March 23, 2010

08:30-10:30

**Plenary Session 3:
Translational Medicine
in Multiple Myeloma**
Forum

Chairperson: Jesús F. San Miguel, University of Salamanca, Salamanca, Spain

Biology of myeloma: Basis for novel drugs*
Jesús F. San Miguel, University of Salamanca, Salamanca, Spain

Translating multiple myeloma stem cells*
William H. Matsui, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Targeting the ubiquitin-proteasome pathway in myeloma therapy
Robert Z. Orlowski, UT M. D. Anderson Cancer Center, Houston, TX, USA

10:30-11:30

Coffee Break
Forum Lounge

10:30-12:30

Poster Session B
Forum Lounge

12:30-13:30

Lunch
Ruby Lounge

13:30-15:30

**Concurrent Session 3:
Circulating Tumor Cells
and Stem Cells**
Forum

Chairperson: Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Detection, clinical relevance, and molecular characteristics of circulating tumor cells*
Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Enumeration and characterization of CTCs*
Stefan Sleijfer, Erasmus Medical Center, Rotterdam, The Netherlands

Molecular analysis of single disseminated tumor cells
Christoph A. Klein, University of Regensburg, Regensburg, Germany

Molecular characterization of circulating tumor cells in breast cancer

Minetta C. Liu, Lombardi Comprehensive Cancer Center, Washington, DC, USA

13:30-15:30

**Concurrent Session 4:
Pharmacogenomics, Drug
Resistance, and Toxicity**
E102

Chairperson: Eddie Reed, University of South Alabama, Mobile, AL, USA

Pharmacogenetic considerations with molecularly targeted therapy
Sharyn D. Baker, St. Jude Children's Research Hospital, Memphis, TN, USA

Genome-wide discovery and clinical validation of pharmacogenomic markers for chemotherapy*
R. Stephanie Huang, University of Chicago, Chicago, IL, USA

Genetic polymorphisms of ABC transporters in cancer chemotherapy: Development of SmartAmp2 method for clinical genetic testing*
Toshihisa Ishikawa, RIKEN Yokohama Institute, Yokohama, Japan

Factors that influence the regulation of ERCC1 in drug resistant cells*
Eddie Reed, University of South Alabama, Mobile, AL, USA

15:30-16:00

Coffee Break
Forum Lounge

16:00-18:30

**Plenary Session 4:
Immunotherapy: Vaccines**
Forum

Chairperson: Laurence Zitvogel, Institute Gustave-Roussy, Villejuif, France

Immunostimulation versus immunosuppression: The woes of cancer vaccine development
Alexander M.M. Eggermont, Erasmus Medical Center, Rotterdam, The Netherlands

Therapeutic vaccines for prostate cancer
James L. Gulley, National Cancer Institute, Bethesda, MD, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Conference Program and Schedule

Augmenting the immune response to prostate cancer with CTLA-4 blockade

Eric J. Small, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

A new era for dendritic cell vaccines

Gerold Schuler, University Hospital of Erlangen, Erlangen, Germany

Immunotherapy of established lesions caused by high-risk HPV*

Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands

Wednesday, March 24, 2010

08:30-10:30

Plenary Session 5: Targets Across Tumor Types Forum

Chairperson: Keith T. Flaherty, Massachusetts General Hospital, Boston, MA, USA

Targeting the nexus of heat shock and metabolic stress responses in cancer*

Kapil N. Bhalla, Medical College of Georgia, Augusta, GA, USA

BRAF mutant melanoma as the proving ground for the MAP kinase pathway as a therapeutic target

Keith T. Flaherty, Massachusetts General Hospital, Boston, MA, USA

Hedgehog pathway inhibitors in cancer

Josina C. Reddy, Genentech, Inc., South San Francisco, CA, USA

Targeting DNA repair mechanisms

E. Ruth Plummer, Northern Centre for Cancer Treatment, Newcastle upon Tyne, United Kingdom

10:30-10:45

Coffee Break Forum Lounge

10:45-12:45

Plenary Session 6: Resistance to Targeted Therapies

Forum

Chairperson: Tito Fojo, NCI-DHHS, Bethesda, MD, USA

Resistance to targeted therapies in a realistic mouse breast cancer model*

Piet Borst, Netherlands Cancer Institute, Amsterdam, The Netherlands

Resistance to VEGF-targeted therapies

Napoleone Ferrara, Genentech, Inc., South San Francisco, CA, USA

Antibody-initiated cancer immunotherapy*

Louis M. Weiner, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA

Title to be announced

Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

12:45-14:00

Lunch

Ruby Lounge

14:00-15:30

Plenary Session 7: Epigenetics Forum

Chairperson: Susan E. Bates, National Cancer Institute, Bethesda, MD, USA

Cancer epigenetics: From DNA methylation to microRNAs

Manel Esteller, Hospital Duran i Reynals, Barcelona, Spain

Targeting histone methyl transferase and demethylases in cancer

Kristian Helin, University of Copenhagen, Copenhagen, Denmark

HDAC inhibitor activity in lymphomas and resistance in solid tumors: Overcoming the impasse

Susan E. Bates, National Cancer Institute, Bethesda, MD, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.